Ypsomed carves out diabetes business in $512M deal to focus on GLP-1 self-injectors

Fierce Biotech2 weeks agoLast Updated: April 23, 2025

Less than a minute

عاجل . أهم الأخبار BREAKING NEWS — After selling off a portion of its diabetes care business last year, Ypsomed is now fully exiting the diabetes care business with a plan to trade its insulin pump development arm and rema | Ypsomed plans to trade its insulin pump arm to a new Swiss medtech, TecMed, in a deal worth up to 420 million francs or about $513 million.

After selling off a portion of its diabetes care business last year, Ypsomed is now fully exiting the diabetes care business with a plan to trade its insulin pump development

Fierce Biotech2 weeks agoLast Updated: April 23, 2025

Less than a minute

Read Next

Learning the business of entrepreneurship: Alexander Saigh

Masimo to Sell Consumer Audio Business to HARMAN International

National Australia Bank’s first-half cash earnings up 1% on lending volume growth

‘It’s really nice that they promote us’: Celebrate Small Business Week in Lebanon

National Australia Bank Profit Tops Estimates on Business Loans

Solana (SOL) Eyes $152.80: Will The Bullish Trend Continue?

New Business Polling Reveals The Unstoppable March Of Clean Power

Related Articles

Leave a Reply Cancel reply

XRP News: XenDex Presale To Hit Soft Cap In Few Hours, $XDX Price Rises After Soft Cap Sell Out, Secure Your XDX Now!

‘Demand is through the roof’: inside America’s trailer park boom

JPMorgan sees signs of ‘Trump exhaustion.’ Why that could keep stocks stuck in a range

Ripple’s Joe Vollono Tapped To Lead BizDev for Stablecoin Challenger Pi Protocol

Solana’s (SOL) 2025 Peak: When It Could Come And The Price To Expect

Britain’s NatWest says Q1 profit rises 36% on stronger income

Forex: Multiple moves on the FX chessboard

Continued job growth could help ward off a recession, Jim Cramer says

Shares of Gucci-owner Kering drop 5% after first-quarter sales slump